Pharmaceutical Overview
Letrozole is a third-generation non-steroidal aromatase inhibitor pharmaceutical compound belonging to the triazole class of enzyme inhibitors. Originally developed and manufactured by pharmaceutical companies for clinical applications, this compound has become an essential research tool for scientists investigating estrogen biosynthesis pathways and hormonal regulation mechanisms. The compound works through competitive inhibition of the aromatase enzyme (CYP19A1), which catalyses the conversion of androgens to estrogens in various tissue types. Researchers at Stroid UK Shop can access this pharmaceutical-grade compound for comprehensive laboratory investigations into endocrine system modulation.
Laboratory Research Applications
Scientific studies utilise letrozole to examine aromatase enzyme function and estrogen production mechanisms in controlled laboratory environments. The compound’s high potency and selectivity make it valuable for researchers studying hormonal feedback loops, reproductive biology, and endocrine disruption models. Investigators frequently employ this compound alongside other hormonal modulators when examining post-cycle recovery protocols in experimental settings. Research applications extend to studies of bone metabolism, cardiovascular health markers, and tissue-specific estrogen receptor activity. Scientists working with aromatase inhibitors often compare letrozole’s mechanism with other compounds in the same therapeutic class. The pharmaceutical nature of this compound ensures consistent potency and purity standards essential for reproducible research outcomes across different experimental protocols and laboratory settings.
Technical Specifications
| Parameter | Value |
|---|---|
| Chemical Name | 4,4′-(1H-1,2,4-triazol-1-ylmethylene)dibenzonitrile |
| CAS Number | 112809-51-5 |
| Molecular Formula | C₁₇H₁₁N₅ |
| Molecular Weight | 285.30 g/mol |
| Purity | Pharmaceutical grade |
| Storage | Room temperature, dry environment |
| Solubility | Poorly water-soluble, DMSO compatible |
| Half-life | Approximately 2 days (research models) |
Research teams investigating metabolic pathways often combine letrozole studies with SARMs research to understand comprehensive hormonal interactions. The compound’s pharmaceutical origin ensures batch-to-batch consistency crucial for longitudinal studies examining endocrine system responses. Scientists studying tissue-specific estrogen activity frequently incorporate peptide compounds alongside letrozole to examine complex hormonal cascades and receptor-mediated signalling pathways in controlled laboratory conditions.
Research Compliance Statement
This letrozole pharmaceutical product is intended exclusively for qualified researchers conducting in-vitro laboratory studies and analytical testing procedures. The compound is not approved for human consumption, therapeutic use, or any application outside controlled scientific research environments. Researchers must ensure proper laboratory protocols, safety procedures, and regulatory compliance when handling this material. All experimental work should be conducted by trained personnel in appropriate laboratory facilities with proper ventilation and safety equipment. This product is sold solely for research purposes and scientific investigation into aromatase enzyme mechanisms and estrogen biosynthesis pathways.
